Haya Ascher-Svanum

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi The burden of depressive symptoms in the long-term treatment of patients with schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland at Baltimore, School of Medicine, USA
    Schizophr Res 90:186-97. 2007
  2. ncbi The cost of relapse and the predictors of relapse in the treatment of schizophrenia
    Haya Ascher-Svanum
    US Outcomes Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 10:2. 2010
  3. ncbi Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA
    Curr Med Res Opin 27:115-22. 2011
  4. ncbi Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN, USA
    J Med Econ 15:531-47. 2012
  5. ncbi Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example
    Douglas E Faries
    Lilly USA, LLC, Indianapolis, Indiana, USA
    Cost Eff Resour Alloc 7:11. 2009
  6. ncbi Item response analysis of the Positive and Negative Syndrome Scale
    Darcy A Santor
    School of Psychology, University of Ottawa, Ottawa, Canada, and The Provincial Centre of Excellence for Child and Youth Mental Health, Ottawa, Ontario, Canada
    BMC Psychiatry 7:66. 2007
  7. ncbi Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 26:2403-10. 2010
  8. ncbi Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia
    H Ascher-Svanum
    Lilly Corporate Center, DC 4133, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Eur Psychiatry 26:313-9. 2011
  9. ncbi Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 10:11. 2010
  10. ncbi Patient education about schizophrenia: initial expectations and later satisfaction
    H Ascher-Svanum
    Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Issues Ment Health Nurs 22:325-33. 2001

Detail Information

Publications66

  1. ncbi The burden of depressive symptoms in the long-term treatment of patients with schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland at Baltimore, School of Medicine, USA
    Schizophr Res 90:186-97. 2007
    ..To prospectively measure the link between depressive symptoms and functional outcomes in the long-term treatment of people with schizophrenia...
  2. ncbi The cost of relapse and the predictors of relapse in the treatment of schizophrenia
    Haya Ascher-Svanum
    US Outcomes Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 10:2. 2010
    ..To assess the direct cost of relapse and the predictors of relapse during the treatment of patients with schizophrenia in the United States...
  3. ncbi Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA
    Curr Med Res Opin 27:115-22. 2011
    ..The objective of this study was to compare the cost-effectiveness of olanzapine to aripiprazole in the treatment of schizophrenia from the perspective of public payers in the United States...
  4. ncbi Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN, USA
    J Med Econ 15:531-47. 2012
    ..The study also compared olanzapine ODT with risperidone and aripiprazole, two other atypical antipsychotics available in both ODT and SOT formulations...
  5. ncbi Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example
    Douglas E Faries
    Lilly USA, LLC, Indianapolis, Indiana, USA
    Cost Eff Resour Alloc 7:11. 2009
    ..Given the importance of quality economic research on the cost of switching treatments, thorough sensitivity analyses should be performed to identify the impact of crisis events around the time of medication change...
  6. ncbi Item response analysis of the Positive and Negative Syndrome Scale
    Darcy A Santor
    School of Psychology, University of Ottawa, Ottawa, Canada, and The Provincial Centre of Excellence for Child and Youth Mental Health, Ottawa, Ontario, Canada
    BMC Psychiatry 7:66. 2007
    ....
  7. ncbi Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 26:2403-10. 2010
    ..To identify reasons for discontinuation and continuation of antipsychotic medications in the treatment of schizophrenia from the patients' and their clinicians' perspectives...
  8. ncbi Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia
    H Ascher-Svanum
    Lilly Corporate Center, DC 4133, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Eur Psychiatry 26:313-9. 2011
    ..This post-hoc analysis assessed supplementation of olanzapine long-acting injection (olanzapine-LAI) with oral olanzapine...
  9. ncbi Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 10:11. 2010
    ..This study assessed the prevalence of encounters with the criminal justice system, encounter types, and the estimated cost attributable to these encounters in the one-year treatment of persons with schizophrenia...
  10. ncbi Patient education about schizophrenia: initial expectations and later satisfaction
    H Ascher-Svanum
    Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Issues Ment Health Nurs 22:325-33. 2001
    ..Content areas that were rated less helpful included prevalence of schizophrenia, its psychosocial rehabilitation, and use of community resources. Implications for clinical practice in patient education are identified and discussed...
  11. ncbi Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Bull 34:1163-71. 2008
    ..This study assessed the predictive accuracy of early nonresponse to treatment and its clinical, functional, and economic ramifications in the naturalistic treatment of predominately chronic outpatients treated for schizophrenia...
  12. ncbi Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 9:46. 2009
    ....
  13. ncbi Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
    Nicolas M Furiak
    Eli Lilly and Company, Indianapolis, IN, USA
    Cost Eff Resour Alloc 7:4. 2009
    ..Olanzapine may, therefore, be a cost-effective therapeutic option for patients with schizophrenia...
  14. ncbi Clinical comparability of schizophrenia patients at two public mental health systems
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, Indiana, USA
    Adm Policy Ment Health 30:231-45. 2003
    ....
  15. ncbi A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychiatry 67:1114-23. 2006
    ..This study aimed to prospectively identify the best single predictor and the best set of predictors of risk for nonadherence with anti-psychotic medication in the treatment of patients with schizophrenia...
  16. ncbi The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting
    Haya Ascher-Svanum
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind 46285, USA
    Am J Manag Care 10:20-4. 2004
    ..To examine the use and economic cost of antiparkinsonian agents during the medication management of patients diagnosed with schizophrenic disorders in a naturalistic healthcare setting...
  17. ncbi Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care
    Haya Ascher-Svanum
    Eli Lilly and Co, Indianapolis, Ind, USA
    J Clin Psychiatry 67:453-60. 2006
    ....
  18. ncbi Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
    Haya Ascher-Svanum
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
    BMC Psychiatry 5:3. 2005
    ..This study assessed the impact of acute treatment-emergent weight gain on clinical and functional outcomes of patients with schizophrenia by patient gender and antipsychotic treatment (olanzapine or haloperidol)...
  19. ncbi Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
    Haya Ascher-Svanum
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 6:8. 2006
    ..This naturalistic study compares atypical and typical antipsychotics on time to all-cause medication discontinuation, a recognized index of medication effectiveness in the treatment of schizophrenia...
  20. ncbi Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic
    Haya Ascher-Svanum
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Psychopharmacol 19:110-7. 2005
    ..88, p 0.05). Treatment-emergent weight gain appears to be an important marker of symptom reduction, and may not be exclusively attributable to pharmacological perturbations...
  21. ncbi Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Res 118:176-82. 2010
    ..In this study, we assessed the effects of early response/non-response to an atypical antipsychotic across multiple outcome measures...
  22. ncbi Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:453-61. 2006
    ..Greater improvement in positive symptoms and a greater study completion rate may hold relevance to enhanced functional outcomes observed after OLZ therapy...
  23. ncbi Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 35:581-90. 2010
    ....
  24. ncbi Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Res 102:230-40. 2008
    ..To test whether early onset of response to antipsychotic medications accurately predicts subsequent response in the treatment of patients with schizophrenia...
  25. ncbi Predictors of switching antipsychotic medications in the treatment of schizophrenia
    Allen W Nyhuis
    Eli Lilly and Company, Indianapolis, IN USA
    BMC Psychiatry 10:75. 2010
    ..To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia...
  26. ncbi Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
    Stephen J Ruberg
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 11:23. 2011
    ..To identify a simple decision tree using early symptom change to predict response to atypical antipsychotic therapy in patients with (Diagnostic and Statistical Manual, Fourth Edition, Text Revised) chronic schizophrenia...
  27. ncbi Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms
    Virginia L Stauffer
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Res 134:195-201. 2012
    ..This distinction, incorporating an evaluation of the presence of positive, affective, and extrapyramidal symptoms, may therefore not have prognostic implications for the responsiveness of patients' negative symptoms to treatment...
  28. ncbi Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
    Douglas Faries
    Outcomes Research, Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 5:26. 2005
    ..This study assessed the annual rate and duration of antipsychotic monotherapy and its inverse, antipsychotic polypharmacy, among schizophrenia patients initiated on commonly used atypical antipsychotic medications...
  29. ncbi Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial
    Sandra L Tunis
    US Medical Division, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Value Health 9:77-89. 2006
    ..029). CONCLUSIONS: Approaches that integrate costs, effectiveness, and treatment patterns are important for providing optimal information regarding the value of first-line antipsychotic options for schizophrenia...
  30. ncbi Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia
    Douglas E Faries
    Eli Lilly and Co, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Curr Med Res Opin 24:1399-405. 2008
    ..Switching medications is common in the treatment of schizophrenia. This study examines the effectiveness of olanzapine therapy following a clinically warranted switch from risperidone during treatment of patients with schizophrenia...
  31. ncbi Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
    Douglas E Faries
    US Statistics, Lilly USA, LLC, Indianapolis, IN, USA
    BMC Psychiatry 9:54. 2009
    ..The goal of this research was to assess the clinical and economic ramifications of switching antipsychotics during outpatient management of schizophrenia...
  32. ncbi Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis
    Virginia L Stauffer
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychiatry Res 187:42-8. 2011
    ..As had been seen in the treatment of patients with chronic schizophrenia, early non-response was a robust predictor of subsequent non-response in the treatment of patients with first-episode psychosis...
  33. ncbi Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model
    Nicolas M Furiak
    Medical Decision Modeling Inc, Indianapolis, IN, USA
    Curr Med Res Opin 27:713-30. 2011
    ....
  34. ncbi Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
    Haya Ascher-Svanum
    Global Health Outcomes, Eli Lilly and Company, USA
    BMC Psychiatry 11:152. 2011
    ..This study assessed whether early response predicted later response when using a long-acting injection (LAI) antipsychotic...
  35. ncbi A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms
    Bruce J Kinon
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:157-62. 2006
    ..The objective of this study is to compare olanzapine with ziprasidone therapy in patients with schizophrenia or schizoaffective disorder and experiencing depressive symptoms...
  36. ncbi Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study
    Haya Ascher-Svanum
    U S Outcomes Research, Eli Lilly and Co, Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA
    J Clin Psychiatry 69:1580-8. 2008
    ..The objective of this study was to compare the 3-year course of schizophrenia between persons with tardive dyskinesia (TD) and persons without TD on multiple outcome measures...
  37. ncbi Analysis of treatment effectiveness in longitudinal observational data
    Douglas Faries
    Outcomes Research, Eli Lilly and Company, Indianapolis, Indiana, USA
    J Biopharm Stat 17:809-26. 2007
    ..Marginal structural models are a promising approach to estimation of causal treatment effects in such data...
  38. ncbi Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan
    Wenyu Ye
    Eli Lilly Japan K K, Kobe, Japan
    Psychiatry Clin Neurosci 66:313-21. 2012
    ..This study assessed clinical and functional outcomes following a switch from risperidone to olanzapine in a 1-year naturalistic study of schizophrenia patients in Japan...
  39. ncbi The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial
    Lei Chen
    Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 11:203. 2011
    ..In this exploratory study, we characterized the relationships among six clinical, functional, cognitive, and quality-of-life measures, identifying a parsimonious set of measurements...
  40. ncbi Cost of antipsychotic polypharmacy in the treatment of schizophrenia
    Baojin Zhu
    Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 8:19. 2008
    ..This study compared the costs of antipsychotic polypharmacy for patients who initiated on 1 of the 3 most commonly prescribed atypical antipsychotics - olanzapine, quetiapine, or risperidone...
  41. ncbi Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods
    Lei Chen
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA
    Schizophr Res 113:34-40. 2009
    ..Identify the optimal magnitude of response to antipsychotic medication at various early time points that best predicts subsequent non-response at 8 weeks...
  42. ncbi Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia
    Baojin Zhu
    Eli Lilly and Company, Lilly Corporate Center Drop 4133, Indianapolis, IN 46285, USA
    Psychiatr Serv 59:315-7. 2008
    ..This study compared the time to discontinuation for any reason of first-generation antipsychotics--in oral versus depot formulation--in the usual care of schizophrenia...
  43. ncbi Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials
    Virginia Stauffer
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Res 130:11-9. 2011
    ..Most patients had modest and sustained improvements during atypical antipsychotic treatment, regardless of their baseline illness severity, representing a partial response to currently available treatments...
  44. ncbi Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia
    Michael M Witte
    Lilly USA, LLC, Indianapolis, IN 46285, USA
    Curr Med Res Opin 28:315-23. 2012
    ..To assess the effects of olanzapine long-acting injection (olanzapine-LAI) on levels of functioning in acutely ill patients with schizophrenia...
  45. ncbi Costs of treating patients with schizophrenia who have illness-related crisis events
    Baojin Zhu
    Eli Lilly and Company, Indianapolis, USA
    BMC Psychiatry 8:72. 2008
    ..This naturalistic prospective study assessed the association of recent crises with mental health treatment costs among persons receiving treatment for schizophrenia...
  46. ncbi Early onset of antipsychotic action in schizophrenia: evaluating the possibility of shorter acute efficacy trials
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 30:286-9. 2010
    ..Early response to antipsychotic treatment discriminated AD from placebo. Reducing placebo-controlled clinical trials from 6 weeks to 2 to 4 weeks was found to be a viable option for efficacy identification in acutely ill patients...
  47. ncbi Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder
    Eduardo Dunayevich
    Outcomes Research, Eli Lilly and Co, Indianapolis, IN, USA
    J Clin Psychiatry 68:1163-71. 2007
    ..This study examines whether longer time to all-cause medication discontinuation is also linked to better functional outcomes...
  48. ncbi The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 28:544-9. 2008
    ..Early improvement in positive or depressive/anxiety symptoms is especially predictive of treatment persistence...
  49. ncbi Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials
    Virginia Stauffer
    Lilly Research Laboratories, Indianapolis, IN, USA
    BMC Psychiatry 9:13. 2009
    ..This post-hoc analysis describes maintenance of response over 24 or 28 weeks in people treated for schizophrenia with olanzapine, risperidone, quetiapine, ziprasidone, or aripiprazole...
  50. ncbi Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
    Hong Liu-Seifert
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    BMC Psychiatry 11:87. 2011
    ..We also assessed the links between productivity level and other clinical outcomes...
  51. ncbi Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study
    Gebra B Cuyún Carter
    Eli Lilly and Company, Global Health Outcomes, Indianapolis, IN 46285, USA
    BMC Psychiatry 11:143. 2011
    ....
  52. ncbi Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs
    Sandra L Tunis
    US Medical Division, Eli Lilly and Company, Indianapolis, Indiana, USA
    Pharmacoeconomics 22:1-8. 2004
    ....
  53. ncbi Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy
    Xiaomei Peng
    Eli Lilly and Company, Indianapolis, Indiana, USA
    Clinicoecon Outcomes Res 3:79-87. 2011
    ....
  54. ncbi Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder
    Baojin Zhu
    Eli Lilly and Company Lilly Research Laboratories, Indianapolis, IN, USA
    Curr Med Res Opin 23:2805-14. 2007
    ..Atypical antipsychotics are playing an increasing role in the treatment of bipolar disorder. The objective of this study was to assess the medication treatment patterns and costs associated with different atypical antipsychotics...
  55. ncbi Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial
    Douglas Faries
    Eli Lilly and Company, Lilly Corporate Center, DC 5024, Indianapolis, IN 46285, USA
    BMC Med Res Methodol 12:142. 2012
    ....
  56. ncbi Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Outcomes Research, Indianapolis, IN, USA
    Patient Prefer Adherence 2:67-77. 2008
    ..To compare adherence and persistence to typical versus atypical antipsychotics and between specific atypical agents in the usual care of schizophrenia and to examine the association between adherence and persistence...
  57. ncbi Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study
    Virginia S Haynes
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 12:222. 2012
    ..This post-hoc analysis of a 3-year study compared the costs of mental health services and functional outcomes between individuals with schizophrenia who met or did not meet cross-sectional symptom remission at study enrollment...
  58. ncbi Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
    Haya Ascher-Svanum
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    Neuropsychiatr Dis Treat 8:113-8. 2012
    ..Current findings are consistent with physicians' stated reasons for switching versus augmenting antipsychotics in the treatment of schizophrenia. Confirmation of these findings requires further research...
  59. ncbi Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia
    Hong Liu-Seifert
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Patient Prefer Adherence 1:9-17. 2007
    ..Associations of patient beliefs about medication with clinical psychopathology and their life satisfaction were also assessed...
  60. ncbi Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools
    Jamie Karagianis
    Eli Lilly Canada Inc, Toronto, Ontario, Canada
    Curr Med Res Opin 23:2551-7. 2007
    ....
  61. ncbi Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
    Xiaomei Peng
    Eli Lilly and Company, Indianapolis, IN, USA
    Clinicoecon Outcomes Res 3:9-14. 2011
    ..To assess change in hospitalization and cost of care from 6 months pre- to 6 months post-initiation on any depot antipsychotic among schizophrenia patients...
  62. ncbi Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
    Haya Ascher-Svanum
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Int J Gen Med 5:391-8. 2012
    ....
  63. ncbi Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone
    Mark Olfson
    Division of Clinical and Genetic Epidemiology, New York State Psychiatric Institute, New York, NY, USA
    Schizophr Bull 33:1379-87. 2007
    ..This study compares 3 cohorts of patients with schizophrenia before, during, and after initiating treatment with fluphenazine decanoate (FD), haloperidol decanoate (HD), or long-acting injectable risperidone (LAR)...
  64. ncbi Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia
    Lizheng Shi
    Department of Health Systems Management, School of Public Health and Tropical Medicine, Tulane University, 1440 Canal St, Suite 1900, New Orleans, LA 70112, USA
    Psychiatr Serv 58:482-8. 2007
    ....
  65. ncbi Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program
    Jeonghoon Ahn
    University of Southern California, Los Angeles, CA, USA
    Value Health 11:48-56. 2008
    ..This study identifies latent classes defined by varying degrees of adherence to antipsychotic drug therapy and examines the sociodemographic, clinical, and resource utilization correlates associated with membership in each adherence class...
  66. ncbi Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use
    David A Smelson
    J Clin Psychopharmacol 26:666-7. 2006